Heart Pump Device Market

Heart Pump Device Market Forecast and Outlook By FMI

In 2025, the heart pump device market was valued at USD 4.8 billion. Based on Future Market Insights’ analysis, demand for heart pump devices is estimated to grow to USD 5.5 billion in 2026 and USD 23.2 billion by 2036. FMI projects a CAGR of 15.4% during the forecast period. Growth is held up by widening eligibility for durable support in advanced heart failure and by ICU shock pathways that increasingly use percutaneous support, while costs, adverse-event management, and centre capability requirements keep uptake concentrated in specialized hospitals.

As Daniel Timms, Founder and Chief Technical Officer of BiVACOR, noted regarding the first-in-human total artificial heart milestone, “I’m incredibly proud to witness the successful first-in-human implant of our TAH. This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute. Utilizing advanced MAGLEV technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial. [1]” The near-term implication is that the product roadmap is widening beyond LVAD iteration into full-replacement platforms, which raises the ceiling for future procedure volumes, but also increases the evidence burden for payers and guideline bodies.

Summary of Heart Pump Device Market

• Heart Pump Device Market Definition
  • The market covers mechanical circulatory support devices, implantable and extracorporeal, used to sustain blood flow in advanced heart failure and cardiogenic shock, procured mainly by tertiary hospitals and specialist cardiac centres.
• Demand Drivers in the Market
  • Heart failure prevalence and ageing demographics expand the eligible cohort and increase referral into advanced therapy pathways. [5]
  • Transplant scarcity and prolonged waiting times push higher use of bridge strategies and destination therapy, sustaining durable LVAD demand. [6]
  • Evidence-led shock protocols and cath-lab adoption of percutaneous support expand use in AMI-related cardiogenic shock episodes. [3]
• Key Segments Analyzed in the FMI Report
  • Type: Implanted heart pump devices lead (68.7% in 2025) as long-duration therapy cohorts expand in transplant-constrained systems.
  • Product: LVADs lead (69.7% in 2025), while total artificial hearts progress from clinical milestones toward early commercial pathways.  
  • Geography: North America and Western Europe set reimbursement and protocol benchmarks, while East Asia and South Asia & Pacific add incremental patient volumes through tertiary-care expansion and transplant ecosystem buildout. [6]  
• Analyst Opinion at FMI
  • Sabyasachi Ghosh, Senior Analyst for Medical Devices at Future Market Insights, opines, ‘In the updated version of the Heart Pump Device Market Report for 2026 to 2036, CXOs will find that adoption is governed by coverage rules, centre accreditation, and complication economics more than device miniaturisation. My analysis tracks how haemocompatibility event control, field-action readiness, and centre enablement programmes convert into contracting leverage and share gains.’
• Strategic Implications/Executive Takeaways
  • Prioritise payer-facing evidence packages linked to readmissions, adverse-event rates, and total episode cost because reimbursement sets the utilisation ceiling. [6]
  • Invest in centre enablement, proctoring, and troubleshooting infrastructure to expand implant-capable footprints in high-growth countries without diluting outcomes.
  • Build rapid field-action playbooks and dual-source critical components to protect hospital confidence when safety notices or kit issues arise. [4]
• Methodology
  • Hybrid procedure-led top down and bottom up modelling validated through primary interviews with cardiac surgeons, heart failure cardiologists, perfusion teams, and hospital procurement leaders.
  • Desk research anchored in regulator communications, payer coverage rules, and national transplant reporting, with triangulation against clinical pathway and centre capability indicators. [4] 
  • All assumptions stress-tested against verifiable disclosures and published clinical evidence, with updates triggered by safety notices, coverage revisions, and major product or trial milestones. [3]  

India (17.8% CAGR) and China (17.2% CAGR) are projected to accelerate through tertiary-care expansion and rising advanced heart failure case finding, while South Korea (16.9% CAGR) advances via reimbursement-linked centre buildout. The United Kingdom (15.8% CAGR) and Japan (14.6% CAGR) expand through structured transplant and MCS programmes with measured patient selection. Mature markets such as the United States (13.5%), Germany (13.9%), and France (13.2%) generate a mix of replacement and pathway broadening, with growth constrained by donor availability, complication management costs, and strict centre criteria.

Heart Pump Device Market Definition

The heart pump device market covers mechanical circulatory support devices used to assist or replace cardiac pumping function in severe heart failure or acute cardiogenic shock. It includes implantable pumps such as LVADs and total artificial hearts, plus extracorporeal systems used in hospitals such as ECMO and balloon pumps. Buyers are mainly hospitals and specialist cardiac centres that use these devices for bridge-to-transplant, bridge-to-recovery, or long-term therapy when transplantation is not available or not suitable.

Market inclusions

This report covers global and regional market sizing for 2026 to 2036, with historical anchoring for 2025. It includes segmentation by type, product, and end use, plus region and selected country-level forecasts. The scope includes adoption drivers tied to reimbursement, transplant constraints, and clinical pathway design, alongside competitive positioning, pipeline signals, and selected regulatory and safety events relevant to device utilisation.

Market exclusions

This scope excludes pharmaceuticals for heart failure, remote monitoring software sold as standalone platforms, and general ICU consumables not specific to mechanical circulatory support. It also excludes downstream rehabilitation services, home-care nursing services, and non-device transplant infrastructure spending. Paediatric-only devices are not modelled as a separate market unless sold into the same commercial portfolio and purchasing channel as adult systems.

Heart Pump Device Market Research Methodology

• Primary research: FMI conducts interviews with cardiac surgeons, heart failure cardiologists, perfusionists, hospital procurement leads, and device OEM product managers to map procedure volumes, pathway changes, and purchasing criteria.
• Desk research: FMI reviews regulator communications, payer coverage rules, guideline statements, device safety notices, company disclosures, and national transplant activity reporting to validate adoption constraints and utilisation patterns. [4]  
• Market-sizing and forecasting: FMI uses a hybrid model combining bottom-up procedure-based estimates (implant and support episodes) with top-down hospital spending and device shipment triangulation, then applies country-level adoption curves linked to centre availability and reimbursement.
• Data validation and update cycle: Forecast outputs are cross-checked against historical procedure signals, payer rule changes, major safety events, and disclosed portfolio updates, then refreshed when new regulator notices, national transplant reporting, or company evidence changes the addressable cohort.

Segmental Analysis

Heart Pump Device Market Analysis by Type

Based on FMI’s heart pump device market report, consumption of implanted heart pump devices is estimated to hold 68.7% share in 2025. Implantable systems dominate because they support long-duration therapy outside the ICU and fit destination-therapy pathways when transplant supply is limited, making them central to advanced heart failure programmes.

• Label shift: Abbott reported an FDA-approved labelling update supporting an aspirin-free regimen for HeartMate 3 patients, a practical signal aimed at bleeding-risk management that can influence centre preference and protocol design. [2]
• Safety discipline: The FDA classified a HeartMate 3 LVAS implant kit recall as Class I due to risks tied to blood leakage or air entering the system, reinforcing procurement focus on kit integrity and field-action readiness. [4]
• Category expansion: BiVACOR’s first-in-human total artificial heart milestone raises the strategic ceiling for implanted solutions by extending beyond assist to full replacement, expanding long-run addressable cohorts if outcomes scale. [1]

Heart Pump Device Market Analysis by Product

Based on FMI’s heart pump device market report, consumption of left ventricular assist devices (LVAD) is estimated to hold 69.7% share in 2025. LVADs lead because left-sided failure is the most common mechanical support indication, and LVAD pathways are supported by established centre experience and payer frameworks.

• Shock pathway evidence: In AMI-related cardiogenic shock, the DanGer Shock trial summary reports a mortality reduction with Impella support versus standard care, supporting wider cath-lab adoption of percutaneous support protocols in suitable patients. [3]
• Guideline and event focus: The 2024 ISHLT consensus on hemocompatibility-related events in durable VADs reflects how bleeding and thrombotic risk management is central to long-term LVAD outcomes and purchasing evaluation. [7]
• Transplant constraint effect: The UK’s national reporting on heart transplantation activity and waiting-list pressures reinforces the structural role of LVADs as bridge or long-term therapy when donor availability limits transplant throughput. [8]

Heart Pump Device Market Drivers, Restraints, Opportunities

Future Market Insights analysis indicates the market’s size is anchored in a high-severity clinical need: advanced heart failure cohorts that exceed transplant supply, plus acute shock episodes where rapid mechanical support can stabilise patients. Heart failure prevalence data in large markets supports the scale of the treatable pool, but conversion into device therapy depends on referral timing, centre capacity, and payer coverage rules. [5]  

A clear transition is underway from “bridge-to-transplant only” positioning to broader lifetime-support pathways that include destination therapy and multi-year outpatient management. This shifts value from one-time device placement toward longitudinal service capability, remote follow-up, and complication management. At the same time, safety events and hemocompatibility risks keep decision-makers focused on outcomes and total cost of care rather than unit price.  

• Coverage-gated adoption: CMS coverage for destination therapy ties utilisation to FDA indication and patient selection, which makes reimbursement rules a hard constraint on volumes in the United States. [6]
• Complication economics: Pump thrombosis, bleeding, and infection risks drive protocol intensity and raise episode costs, pushing hospitals to favour devices and pathways with measurable adverse-event reductions. [7]
• Centre concentration: Implant volumes track the distribution of advanced heart failure centres and transplant-linked networks, so capacity expansion in India and China can lift volumes faster than in saturated markets.  

Regional Analysis

The market is analysed across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and the Middle East & Africa. Regional forecasts reflect differences in transplant availability, centre capability, payer rules, and the maturity of cardiogenic shock pathways, with the full report providing market attractiveness analysis by country and segment.

Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research

North America Market Analysis

North America functions as the evidence and reimbursement rule-setter for durable LVAD utilisation, with clinical pathways shaped by major academic centres and payer criteria. Abbott (HeartMate portfolio) and Johnson & Johnson’s Abiomed (Impella) are central reference suppliers, and hospital buyers place heavy weight on outcomes evidence, complication profiles, and regulator communications. [2]  

• United States: Demand for heart pump devices in the United States is projected to rise at 13.5% CAGR through 2036. Coverage rules are a primary gate: CMS destination therapy coverage ties reimbursement to FDA-approved indications and defined patient selection, which pushes hospitals to standardise evaluation workflows and centre qualification. [6] Clinical adoption in acute shock also tracks evidence-led protocols, with DanGer Shock results supporting broader consideration of percutaneous support in AMI-related cardiogenic shock for selected patients. [3] Safety and quality systems remain procurement-critical, as illustrated by FDA recall communications affecting implant kits, which can drive immediate inventory checks and supplier scrutiny across implanting centres. [4]
• Canada: Demand for heart pump devices in Canada is projected to rise at 13.1% CAGR through 2036. Utilisation is shaped by the concentration of advanced heart failure and transplant programmes in a limited number of high-volume centres, which tends to centralise procurement and standardise protocols. Canadian hospitals typically align device selection to international evidence and guideline-based haemocompatibility management approaches, since long-term outcomes and complication reduction drive total episode cost and ICU utilisation. [7] Donor constraints remain a background driver for bridge strategies, so devices that reduce adverse events and support outpatient stability carry procurement weight. Canada’s purchasing model often emphasises value-based evaluation, where safety notices and regulator communications can accelerate internal reviews and drive conservative stocking and training practices.

FMI's analysis of heart pump device market in North America consists of country-wise assessment that includes the United States and Canada. Readers can find centre concentration mapping, payer-rule impact assessment, and segment attractiveness by type and product for advanced heart failure and shock pathways.

Western Europe Market Analysis

Western Europe acts as a structured adopter region where guideline alignment, transplant capacity, and national service configuration shape the pace of LVAD and short-term support growth. Abbott’s LVAD franchise and J&J Abiomed’s Impella platform are widely referenced in clinical pathways, while national transplant bodies influence referral timing and therapy selection. [2] 

• United Kingdom: Demand for heart pump devices in the United Kingdom is projected to rise at 15.8% CAGR through 2036. National reporting indicates persistent transplant system pressure, and the 2024/2025 heart transplantation report provides the planning backbone for capacity and pathway decisions across specialist centres. [8] This environment supports LVAD use as bridge and as longer-duration therapy where eligible cohorts exceed donor throughput, with purchasing decisions centred on complication management and service capability rather than device hardware alone. ICU and perioperative standards are also shaped by UK-focused clinical practice resources for LVAD patient management, reinforcing the role of trained multidisciplinary teams and standardised response to bleeding, infection, and device alarms. [7]
• Germany: Demand for heart pump devices in Germany is projected to rise at 13.9% CAGR through 2036. Germany’s advanced heart failure ecosystem is closely tied to European guideline positioning for long-term mechanical support in selected refractory patients, which supports a stable base of LVAD utilisation in high-volume cardiac centres. [9] A notable demand signal comes from ongoing registry-driven practice and published analyses of LVAD therapy trends, which shape hospital protocol choices and training priorities. [9] Procurement emphasis often sits on haemocompatibility risk reduction, complication control, and service readiness, aligning with international consensus focus on durable VAD adverse-event management. [7]

FMI's analysis of heart pump device market in Western Europe consists of country-wise assessment that includes the United Kingdom and Germany. Readers can find transplant-linked pathway modelling, reimbursement and service configuration impacts, and product-level attractiveness for LVAD and percutaneous support systems.

East Asia Market Analysis

East Asia is a capacity-build and localisation region, combining rising advanced heart failure detection with domestic device programmes and growing clinical trial footprints. Local manufacturers in China and Japan’s structured MCS ecosystem influence adoption, while international suppliers remain influential in high-acuity segments.  

• China: Demand for heart pump devices in China is projected to rise at 17.2% CAGR through 2036. A key mechanism is domestic capability building: China’s regulator has previously issued approvals for domestically developed implantable “artificial heart” systems, signalling local industrial commitment to LVAD platforms. [10] Clinical scale signals also come from published experience with domestically used LVAD systems, including reports of post-approval utilisation and multi-centre trial activity, which supports broader physician familiarity and training depth. [11] As domestic platforms mature, hospitals can reduce dependence on imported systems for some cohorts, which can improve affordability and expand eligible patient conversion, particularly in large tertiary centres. [3]
• Japan: Demand for heart pump devices in Japan is projected to rise at 14.6% CAGR through 2036. Japan’s destination therapy pathway has been building with structured patient selection and registry-style learning, and published discussion notes the recording of destination-therapy LVAD cases as the pathway expands. [12] This supports durable implanted device demand in a system where transplant waiting times and donor constraints are relevant decision factors. Care delivery is strongly protocol-led, so haemocompatibility management and adverse-event prevention weigh heavily in centre evaluations, consistent with the focus of 2024 consensus work on durable VAD event management. [7]

FMI's analysis of heart pump device market in East Asia consists of country-wise assessment that includes China and Japan. Readers can find domestic versus imported platform positioning, centre capability mapping, and product adoption curves for LVAD and ICU-based support pathways.

South Asia & Pacific Market Analysis

South Asia & Pacific is the highest incremental volume opportunity region, driven by the expansion of tertiary cardiac care, a rising transplant base, and the creation of structured organ donation and allocation programmes. International suppliers shape high-end care, while local programmes improve conversion of end-stage heart failure patients into advanced therapy pathways. [13]

• India: Demand for heart pump devices in India is projected to rise at 17.8% CAGR through 2036. The adoption mechanism is capacity and system building: national reporting shows growth in deceased donation and deceased transplants between 2016 and 2024, which supports broader transplant-linked cardiac care ecosystems and raises the relevance of bridge-to-transplant strategies. [13] Professional reporting also documents heart transplant activity counts in recent years, reinforcing the expansion of advanced heart failure treatment capacity that often co-develops with mechanical support capability. [14] As tertiary centres expand, LVAD and ECMO utilisation can rise through better referral networks, more perfusion capacity, and improved perioperative protocols.
• South Korea: Demand for heart pump devices in South Korea is projected to rise at 16.9% CAGR through 2036. A strong adoption driver is the maturation of transplant and mechanical support practice: published reporting from the Korean Organ Transplant Registry reflects a growing transplant base and the rising utilisation of mechanical support within advanced cardiac care. [15] This increases the clinical workforce familiarity with MCS management and can raise LVAD candidacy identification. South Korea’s high-tech hospital ecosystem supports protocol-led expansion, with an emphasis on adverse-event management and long-run haemocompatibility risk control aligned with international consensus work. [7]

FMI's analysis of heart pump device market in South Asia & Pacific consists of country-wise assessment that includes India and South Korea. Readers can find transplant-system-linked forecasting, hospital capacity mapping, and segment attractiveness for implantable versus extracorporeal support.

Competitive Aligners for Market Players

The competitive structure is moderately concentrated in core sub-segments. Durable implanted LVAD demand is led by established platforms with deep clinical evidence and centre familiarity, while acute shock support is influenced by cath-lab workflow integration and outcomes evidence. Competitive advantage is shaped less by list price and more by evidence depth, complication management performance, and the ability to train and support centres at scale. [2] 

Companies with structural advantages tend to combine three assets: (1) long-running clinical datasets that satisfy payer and guideline scrutiny, (2) field support infrastructure that reduces downtime and improves adverse-event response, and (3) manufacturing and supply resilience that lowers the operational risk to implanting centres. Safety notices raise the value of strong field-action capability, since hospitals interpret response speed and transparency as part of the product’s risk profile. [4]

Buyer behaviour is increasingly pathway-driven. High-volume hospitals and transplant centres use formal value analysis committees, adverse-event registries, and protocol standardisation to reduce variability. This shifts leverage toward buyers on service terms and post-implant support requirements, while suppliers retain pricing power where switching costs are high due to training, clinical practice standardisation, and installed-base management.

Recent Developments:

• In May 2025, St Vincent’s Hospital Sydney (St Vincent’s clinicians) performed the world’s first-in-human implant of the CorWave Left Ventricular Assist Device (LVAD) (implanted on 28 May) as a bridge-to-transplant option [16].
• In July 2025, King Faisal Specialist Hospital & Research Centre (KFSHRC) performed the world’s first robotic-assisted BiVAD-HMIII implantation (two artificial pumps for biventricular support) for an advanced heart-failure patient [17].
• In April 2025, CoreMedTech (Core Medical) secured >$100 million Series D financing and stated its Corheart 6 LVAD had exceeded 700 cumulative implant surgeries [18].

Key Players in Heart Pump Device Market

• Abbott Laboratories
• Johnson & Johnson (Abiomed, Inc.)
• LivaNova PLC
• Berlin Heart GmbH
• SynCardia Systems, LLC
• CorWave SA
• Jarvik Heart, Inc.
• BiVACOR Inc.
• Medtronic plc
• Terumo Corporation
• Getinge AB

Scope of Report

Heart Pump Device Market Analysis by Segments

Type:

• Implanted Heart Pump Devices
• Extracorporeal Heart Pump Devices

Product:

• Left Ventricular Assist Devices (LVAD)
• Total Artificial Hearts (TAHs)
• Intra-aortic Balloon Pumps (IABPs)
• Extracorporeal Membrane Oxygenation (ECMO)

End use:

• Hospitals
• Cardiac Centers
• Others

Region:

• North America (United States, Canada)
• Latin America
• Western Europe (United Kingdom, Germany, France, Italy, Spain)
• Eastern Europe
• East Asia (China, Japan, South Korea)
• South Asia & Pacific (India, Indonesia, Australia)
• Middle East & Africa

Bibliography

• [1] BiVACOR, Inc. (2024, July 25). The Texas Heart Institute implants BiVACOR total artificial heart. 
• [2] Abbott. (2024, August). FDA approves aspirin-free labeling update for HeartMate 3.
• [3] American College of Cardiology. (2024, April). DanGer Shock: Routine mechanical circulatory support in AMI-related cardiogenic shock.
• [4] USA Food and Drug Administration. (2024, May). Abbott recalls HeartMate 3 left ventricular assist system (LVAS) implant kit for risk of blood leakage or air entering system.
• [5] Elsevier. (2025). Heart failure prevalence reflecting approximately 6.2 million adults in the United States (review summary). ScienceDirect.
• [6] Centers for Medicare & Medicaid Services. (2026). National coverage determination (NCD) for ventricular assist devices (20.9.1).
• [7] International Society for Heart and Lung Transplantation. (2024). 2024 consensus document on hemocompatibility-related events in durable ventricular assist devices (VADs).
• [8] NHS Blood and Transplant. (2025). Annual report on heart transplantation 2024/2025.
• [9] European Society of Cardiology. (2024). National trends and guideline positioning for LVAD therapy (conference supplement). European Heart Journal.
• [10] National Medical Products Administration. (2022, July). China approves domestically developed “artificial heart”.
• [11] Clinical experience and post-approval use of HeartCon-type LVAD in China. (2025). PubMed Central.
• [12] Destination therapy LVAD pathway and recorded DT-LVAD cases in Japan. (2025). PubMed Central.
• [13] National Organ & Tissue Transplant Organisation, Ministry of Health & Family Welfare. (2024). Organ donation and transplantation data (2013-2024).
• [14] Annual report of the Indian Society for Heart and Lung Transplantation (heart transplant counts referenced). (2024). Journal of Patient-Centered Cardiology.
• [15] Third official adult heart transplant report (Korean Organ Transplant Registry analysis). (2024). Korean Circulation Journal.
• [16] St Vincent’s Private Hospital. (n.d.). World first as St Vincent’s clinicians implant revolutionary new heart device. 
• [17] King Faisal Specialist Hospital & Research Centre. (2025, July 16). KFSHRC performs world’s first robotic-assisted BiVAD implantation. 
• [18] 36Kr. (2025, April 23). “Core Medical” secures over $100 million in Series D financing, completes over 700 artificial heart implant surgeries in total 

This Report Addresses

• Market size and 10-year forecast for 2026 to 2036 with a 2025 baseline anchor
• Growth opportunity mapping by type, product, and end use to support portfolio prioritisation
• Country and regional forecasting tied to centre capability, transplant constraints, and coverage rules
• Reimbursement and policy impact assessment, with emphasis on destination therapy coverage rules
• Competitive structure review covering evidence depth, training capability, and field-action readiness
• Regulatory and safety-event tracking relevant to procurement and adoption risk management
• Strategic analysis of pathway shifts from bridge-to-transplant toward lifetime therapy cohorts
• Buyer behaviour analysis on value analysis committees, protocol standardisation, and switching costs